From a therapeutic viewpoint and based on our results, a double-blinded randomized phase 2 clinical trial was conducted on patient with non-acetaminophen acute liver failure, trial that showed significant recovery induced by Reg3α in particular in patients suffering from autoimmune- and HBV-related acute on chronic liver failure [60]. This evidence concerns the gene REG3A and acute liver failure.